跳至主要内容
临床试验/NCT06221605
NCT06221605已完成不适用

Probiotic Supplementation With BLa80, BL21, and LRa05 Stabilizes Lipid Metabolism in Chronic Hepatitis B Patients Receiving Tenofovir Alafenamide: A Clinical Trial

Wecare Probiotics Co., Ltd.1 个研究点 分布在 1 个国家目标入组 84 人开始时间: 2024年3月30日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
84
试验地点
1
主要终点
Test the level of HBV infection in chronic hepatitis B patients

研究概览

简要总结

The goal of this is to verify the clinical efficacy of compound probiotics in reducing HBV infection levels and regulating intestinal flora in patients with chronic hepatitis B.

The main question it aims to answer is:

• Conventional antiviral therapy combined with a 3-month probiotic intervention was used to evaluate the clinical efficacy of reducing HBV infection levels (HBeAg, HBsAg, and HBV DNA levels) and regulating gut microbiota.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Single (Participant)

盲法说明

Double (Participant, Investigator)

入排标准

年龄范围
18 Years 至 80 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Meet the hepatitis B clinical diagnostic criteria of the Chronic Hepatitis B Prevention and Treatment Guidelines (2022 edition), excluding patients infected with hepatitis C virus, hepatitis D virus and other hepatitis viruses;
  • Be aware of the content and purpose of this study, and voluntarily sign the treatment study consent.

排除标准

  • Patients infected within 3 months;
  • Received antibiotic treatment within 3 months;
  • Received probiotic and probiotic therapy within 3 months;
  • Complicated with hypertension or diabetes;
  • Obesity or significantly low weight;
  • Obvious atherosclerosis;
  • Chronic kidney disease;
  • Inflammatory bowel disease, irritable bowel syndrome, or a history of gastrointestinal surgery;
  • Malignant tumors;
  • Autoimmune diseases;
  • Mental illnesses such as Parkinson's disease, Alzheimer's disease and stroke;
  • Pregnant or lactating women;
  • Patients with cirrhosis or decompensated liver disease;
  • Subjects cannot participate in the experiment due to their reasons; Those who meet any of the above criteria will not be selected.

结局指标

主要结局

Test the level of HBV infection in chronic hepatitis B patients

时间窗: 6 months

Evaluate HBsAg level in IU/mL

次要结局

未报告次要终点

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验